Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AC4K | ISIN: US28106W1036 | Ticker-Symbol: 8EM
Tradegate
06.06.25 | 16:13
1,660 Euro
+5,77 % +0,091
1-Jahres-Chart
EDITAS MEDICINE INC Chart 1 Jahr
5-Tage-Chart
EDITAS MEDICINE INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,6981,71816:59
1,6991,71716:59

Aktuelle News zur EDITAS MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoEditas Medicine ändert Aktienplan und erhöht genehmigte Aktien3
MoEditas Medicine, Inc. - 8-K, Current Report1
28.05.Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit51
16.05.Editas Medicine: A Cautionary Tale for Investors4
14.05.Editas Medicine, Inc.: Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June2
14.05.Editas Medicine, Inc.: Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting146Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia...
► Artikel lesen
EDITAS MEDICINE Aktie jetzt für 0€ handeln
13.05.Editas Medicine meldet Durchbruch bei der Behandlung von Lebererkrankungen12
13.05.Editas Medicine reports breakthrough in liver disease treatment3
13.05.Editas Medicine, Inc.: Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting114In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE)...
► Artikel lesen
13.05.Editas Medicine stock target cut to $4 at Evercore ISI3
12.05.Editas Medicine, Inc. - 10-Q, Quarterly Report1
12.05.Editas Medicine, Inc.: Editas Medicine Announces First Quarter 2025 Results and Business Updates337Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs)...
► Artikel lesen
12.05.Editas Medicine, Inc. - 8-K, Current Report1
12.05.Editas zeigt sich optimistisch über CRISPR-Patentverfahren nach Berufung8
12.05.Editas Medicine, Inc.: Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board100CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part...
► Artikel lesen
28.04.Editas Medicine, Inc.: Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting11
21.03.AstraZeneca deepens China investment; Editas loses CFO to Dyne16
20.03.Editas Medicine, Inc. - 8-K, Current Report16
20.03.Editas Medicine appoints new CFO as Lucera steps down3
20.03.Editas Medicine, Inc.: Editas Medicine Announces Chief Financial Officer Transition339Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc....
► Artikel lesen
Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1